CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗：我们身在何处，将走向何方？
英文原题：CAR-T cell therapy: Where are we now, and where are we heading?
查看英文原题
CAR-T cell therapy: Where are we now, and where are we heading?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法治疗血液系统恶性肿瘤已显示出显著疗效，目前已有9种CAR-T 产品可用。此外，CAR-T 细胞还展现出将治疗应用拓展至多种领域的潜力，包括实体瘤、心肌纤维化、自身免疫性疾病和感染性疾病。尽管取得上述进展，治疗相关毒性反应和疾病复发等重大挑战仍然存在。因此，当前研究聚焦于解决这些问题，以提高CAR-T 细胞的安全性和疗效并降低复发率。本文全面综述CAR-T 细胞疗法的现状，包括其成就、现有挑战及潜在未来发展方向。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available.
Furthermore, CAR-T cells have shown promising potential for expanding their therapeutic applications to diverse areas, including solid tumors, myocardial fibrosis, and autoimmune and infectious diseases. Despite these advancements, significant challenges pertaining to treatment-related toxic reactions and relapses persist.
Consequently, current research efforts are focused on addressing these issues to enhance the safety and efficacy of CAR-T cells and reduce the relapse rate. This article provides a comprehensive overview of the present state of CAR-T-cell therapies, including their achievements, existing challenges, and potential future developments.
论文信息
- 作者
- Wang JY、Wang L
- 单位
- Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.China
- 文献类型
- 综述
- 期刊
- Blood science (Baltimore, Md.)2023 Oct
- 原文标识
- PubMed 37941917 · DOI 10.1097/BS9.0000000000000173
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →